These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Sequential treatment with rmIL-3 or simultaneous treatment with rmIL-3 or rhIL-11 with thrombopoietin (TPO) fails to enhance in vivo neonatal rat thrombocytopoiesis.
    Author: van de Ven C, Fernandez GW, Herbst T, Knoppel A, Cairo MS.
    Journal: Exp Hematol; 1997 Aug; 25(9):1005-12. PubMed ID: 9257814.
    Abstract:
    Multipotent-lineage nondominant growth factors, acting alone or in combination with lineage-dominant cytokines, are known to influence both myelopoiesis and thrombocytopoiesis. Interleukin (IL)-3 and IL-11 stimulate and expand multilineage progenitor cells and induce thrombocytopoiesis. These cytokines also act synergistically with various other lineage dominant and lineage-nondominant cytokines in vitro to expand primitive and committed hematopoietic stem cells. In this study we investigated the in vivo effects of IL-3 and IL-11 in combination with the c-mpl ligand, thrombopoietin (rhTPO), on neonatal rat hematopoiesis. Newborn Sprague-Dawley rats (24 36 hours old, weighing 6-8 g) were intraperitoneally injected with rhTPO (10 microg/kg) for 14 days, rmIL-3 (10 microg/kg) for 5 days followed by rhTPO (10 microg/kg) for 9 days, rmIL-3 (10 microg/kg) + rhTPO (10 microg/kg) for 14 days, rhIL-11 (250 microg/kg) + rhTPO (10 microg/kg) for 14 days, or PBS/human serum albumin (HSA) for 14 days. When compared with PBS/HSA, rhTPO at a dosage of 10 microg/kg significantly increased platelet count (10(-9) L) (day 6, 569 +/- 37.1 vs. 1446 +/- 43.8, p < 0.001; day 10, 796 +/- 68.3 vs. 1774 +/- 238.4, p < 0.01; day 14, 850 +/- 64.4 vs. 3441 +/- 98.1 /10(-9) l, p < 0.001) and absolute neutrophil count (ANC) (day 6, 335.2 +/- 59.6 vs. 752 +/- 335.2, p < 0.01; day 12, 664 +/- 54.1 vs. 1520 +/- 158.2, p < 0.01). However, rhTPO has no effect on the circulating hematocrit or red blood cell count. RhTPO-treated animals also displayed higher platelet counts (/10(-9) L) vs. rhIL-11 or rhIL-6 beginning on day 6 (day 6, 1597.6 +/- 134.7 vs. 930.7 +/- 67.3 vs. 863 +/- 19.6, p < 0.01; day 8, 1686 +/- 208.4 vs. 990 +/- 29.4, vs. 977 +/- 34.33, p < 0.05; day 10, 1774 +/- 238.4 vs. 1096 +/- 49.6, vs. 937 +/- 65, p < 0.01; day 14, 2187 +/- 127.5 vs. 1280 +/- 35.8 vs. 951 +/- 50.7 /10(-9) L, p < 0.01). Sequential administration of rmIL-3 followed by rhTPO resulted in no significant increase in platelet counts compared with PBS-HSA/rhTPO. RhTPO + rmIL-3 given simultaneously also had no additive effect on the circulating platelet count compared with rhTPO alone. Similarly, no additive effect on circulating platelet counts was observed with rhIL-11 + rhTPO vs. rhTPO alone. Bone marrow studies showed a significant increase in the number of megakaryocytes per high-power field in all the groups treated with rhTPO vs. control (p < 0.05), but no additive effect was seen in neonatal rats additionally receiving either rmIL-3 or rhIL-11. Colony forming unit (CFU)-Meg colony formation was also significantly increased in all the groups treated with rhTPO vs. control (p < 0.05), with no additive effect observed after the addition of either rmIL-3 or rhIL-11. These data suggest that rhTPO is more effective than rmIL-3 or rhIL-11 in inducing neonatal in vivo thrombocytopoiesis in rats, and that no additive effect is to be expected when rhTPO is combined sequentially with rhIL-3 or simultaneously with either rmIL-3 or rhIL-11. We hope that these preclinical data will provide insight into the design and future application of these thrombopoietic cytokines, alone or in combination, to prevent or treat thrombocytopenia.
    [Abstract] [Full Text] [Related] [New Search]